Bevacizumab
Approved as a biosimilar to Avastin®, bBevacizumab was among the earliest
biologics development programs undertaken by Biocon Biologics, reflecting our
enduring commitment to making high-quality, affordable oncology therapies
accessible. Commercialized in India in 2017 under the brand name Krabeva®, it was
our second biosimilar monoclonal antibody, following bTrastuzumab. Since then, the
product has supported patient care across multiple emerging markets and received
regulatory approvals from the European Medicines Agency (EMA) in 2021 and the
U.S. Food and Drug Administration (FDA) in 2025, under the brand name Abevmy®,
underscoring our robust scientific and regulatory capabilities in oncology biosimilar.
2008-11
Early lab scale development begins with upstream and downstream process optimization, formulation development, and comprehensive analytical characterization to establish biosimilarity with the reference product.
2012-14
The program progresses through late-stage process development and validation activities, setting the stage for clinical trials aimed at demonstrating safety, efficacy, and comparability, ultimately enabling regulatory submissions.
2017
Biosimilar Bevacizumab receives regulatory approval from the Drug Controller General of India and is launched in India under the brand name Krabeva.
2019
Biocon submits the Biologics License Application (BLA) for biosimilar Bevacizumab to the U.S. FDA
2021
Regulatory approvals for biosimilar Bevacizumab are secured from leading global authorities, including the European Medicines Agency (EMA), Health Canada, Therapeutic Goods Administration (TGA), Australia, and Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom.
2025
Jobevne TM receives approval from U.S. FDA.
Biosimilar Bevacizumab was among Biocon’s earliest biologics development programs and reflects our long-standing commitment to advancing affordable oncology therapies. It was Biocon’s second biosimilar monoclonal antibody in the oncology space to be commercialized in India in 2017. The product has also been approved by the EMA in 2021 and U.S. FDA in 2025.
Related Links
At Biocon Biologics, our commitment to transforming diabetes management is reflected in our journey to bring an affordable, high-quality Glargine...
Our Ustekinumab biosimilar represents a breakthrough in immunology, offering a high-quality, accessible treatment option for patients with psoriasis, psoriatic arthritis,...
